CRL: 10-K Risk Factor Changes

2026 vs 2025  ·  SEC EDGAR  ·  2026-06-01
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

9
New Risks
6
Removed
27
Modified
27
Unchanged
🟢 New in Current Filing

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

•Failure to comply with applicable data privacy and security laws in various jurisdictions could subject us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement actions that could have a material adverse effect on our business. •Failure…

Read full text

•Failure to comply with applicable data privacy and security laws in various jurisdictions could subject us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement actions that could have a material adverse effect on our business. •Failure to comply with U.S., state, local or international environmental, health, safety and sustainability laws and regulations could result in fines and penalties and loss of licensure and have a material adverse effect upon the Company’s business. •Changes in U.S. and International Tax Law, results of tax audits, or material changes in our stock price could have a material adverse impact on our effective tax rate and financial results. •Non-clinical and clinical contract research services create a risk of liability. •The failure to successfully obtain, maintain and enforce intellectual property rights and defend against assertions of third parties to intellectual property rights could adversely affect us. •Our by-laws designate the state courts located in the State of Delaware as the sole and exclusive forum for certain actions, which could limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable and may discourage lawsuits with respect to certain claims. •We are involved in legal proceedings that could adversely affect our business, financial condition, and results of operations. •Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition can have an adverse effect on our business and financial statements.

🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟢 New in Current Filing Our review of potential strategic alternatives may not result in an executed or consummated transaction or other strategic alternative, and the process of reviewing strategic alternatives or the outcome could adversely affect our business. 🔒
🟢 New in Current Filing Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business. 🔒
🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟢 New in Current Filing Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition can have an adverse effect on our business and financial statements. 🔒
🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🔴 No Match in Current Filing If we are not successful in selecting and integrating the businesses and technologies we acquire or partner with, or if we do not manage our current and future site closures and divestitures, our business may be adversely impacted. 🔒
🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified Impairment of long-lived tangible assets and intangible assets (such as goodwill and other intangible assets) may adversely impact future results of operations. 🔒
🟡 Modified Failure to execute our business strategy could adversely impact our growth and profitability. 🔒
🟡 Modified We bear financial risk for contracts that may be terminated or reduced in scope, underpriced, subject to cost overruns or delays. 🔒
🟡 Modified Our operations might be affected by the occurrence of a natural disaster or other catastrophic event. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified New technologies may be developed, validated and increasingly used in biomedical research, which could reduce demand for some of our products and services. 🔒
🟡 Modified The industries in which we operate are highly competitive. 🔒
🟡 Modified Our quarterly operating results may vary, which could negatively affect the market price of our common stock. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified If we are unable to attract, hire or retain key team members or a highly skilled global workforce with various backgrounds and experiences, it could have a negative impact on our business, financial condition or results of operations. 🔒
🟡 Modified A reduction or delay in government funding of R&D may adversely affect our business. 🔒
🟡 Modified Business and Operational Risks 🔒
🟡 Modified Demand volatility and risk of credit losses from clients may adversely affect our business. 🔒
🟡 Modified We are required to comply with stringent, complex and evolving laws, rules, regulations and standards in many jurisdictions, as well as contractual obligations, relating to data privacy and security. Any actual or perceived failure to comply with these requirements could have a material adverse effect on our business. 🔒
🟡 Modified We may not be able to successfully develop and market new services and products. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified Changes in government regulation or in practices relating to the pharmaceutical or biotechnology industries, including potential healthcare reform, could decrease the need for the services we provide. 🔒
🟡 Modified If we are not successful in selecting and integrating the businesses and technologies we acquire or partner with, or if we do not manage our current and future site closures and divestitures, our business may be adversely impacted. 🔒
🟡 Modified Contaminations in our animal populations can damage our inventory, harm our reputation for contaminant-free production, result in decreased sales and cause us to incur additional costs. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified Our business is subject to risks relating to operating internationally, including changes in foreign currency exchange rates. 🔒
🟡 Modified We depend on key personnel and may not be able to retain these employees, which could harm our business. 🔒
🟡 Modified Legal and Regulatory Risk Factors 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
41 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →